Business Wire

REVEAL GENOMICS ® HER2DX ® Genomic Test to Be Validated in Pivotal ECOG-ACRIN CompassHER2 pCR Trial in HER2+ Breast Cancer


REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, today announced the forthcoming prospective validation of its groundbreaking diagnostic tool HER2DX® within the framework of the ongoing CompassHER2 pCR Trial. This study is led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), a scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer, comprising nearly 1400 member institutions in the United States and around the world.

This press release features multimedia. View the full release here:

The CompassHER2 pCR Trial (also EA1181) is a single-arm phase II neoadjuvant study that successfully enrolled 2175 patients with stage II or IIIa HER2-positive (HER2+) breast cancer. Now in follow-up, this trial seeks to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with a pathologic complete response (pCR) after 3 months of pre-operative treatment with standard THP (single-agent taxane chemotherapy plus trastuzumab and pertuzumab [HP], both targeted drugs). If testing shows pCR at the time of surgery, patients will then complete a year of HP plus hormonal therapy and radiation, if indicated.

If the study's results validate this approach, it would allow patients to have fewer side effects and better quality of life. The neoadjuvant setting offers the opportunity to use pCR as a functional biomarker to identify patients with excellent outcomes and refine treatment to maximize benefit and minimize toxicity. The primary objective of the trial is 3-year recurrence-free survival, and pCR is a secondary endpoint.

In this collaboration, the CompassHER2 pCR Trial protocol has been amended to include the evaluation of the HER2DX® genomic test as a key secondary correlative endpoint. HER2DX® pCR-score and HER2DX® risk-score will be analyzed in baseline pre-treatment samples from most trial participants, linking these scores directly to patient outcomes.

The principal investigator of the CompassHER2 pCR Trial, Dr. Nadine M. Tung, commented, "Integrating HER2DX®'s predictive capabilities into our trial represents a significant opportunity in our quest to tailor treatments to the individual, not just the cancer type. If proven and validated, this assay could fundamentally change our approach to treating HER2-positive breast cancer."

Previous retrospective validation involving 765 patients with early-stage HER2+ breast cancer who received neoadjuvant therapy highlighted the HER2DX® pCR-score's ability to distinguish patients with a high pCR rate of 80-90% after treatment with single taxane, trastuzumab, and pertuzumab.

REVEAL GENOMICS' CEO, Patricia Villagrasa, added, "The inclusion of HER2DX® in the CompassHER2 pCR Trial is a testament to our commitment to advancing breast cancer treatment. By providing a more nuanced understanding of HER2-positive cancers, HER2DX® will play a crucial role in shaping the future of personalized therapy and improving patient outcomes."

HER2DX® in the CompassHER2 pCR Trial: Guiding the way to personalized medicine

The inclusion of HER2DX® in the CompassHER2 pCR Trial seeks to corroborate these initial findings, providing Level 1 evidence to support the selection of an optimized therapy regimen. Specifically, it seeks to validate the use of a single taxane-based regimen over traditional multi-agent chemotherapy, potentially revolutionizing the treatment approach for HER2-positive breast cancer by enabling more personalized, less intensive treatment strategies.

This pivotal collaboration represents a significant step towards personalized medicine in the management of early-stage HER2-positive breast cancer.

About HER2DX®️

HER2DX®️ is the world’s first diagnostic test formulated specifically for HER2+ breast cancer. Marketed by REVEAL GENOMICS®️ since January 2022, HER2DX® is a standardized 27-gene expression test for patients with early-stage HER2+ breast cancer.

HER2DX®️ is a prognostic, predictive assay based on clinical and genomic data. The test integrates clinical information (i.e. tumor size and nodal status) with biological information tracking immune response, luminal differentiation, tumor cell proliferation, and expression of the HER2 17q12-21 chromosomal amplicon, including the ERBB2 gene.

HER2DX®️ predicts:

  • Risk of relapse score (high vs. low): the risk of recurrence in patients with newly diagnosed HER2+ breast cancer.
  • pCR likelihood score (high vs. medium vs. low): the likelihood of a patient responding to anti-HER2-based treatment before surgery.
  • ERBB2 score (high vs. medium vs. low): the quantitative expression of ERBB2 mRNA across HER2-negative, HER2-low and HER2+ breast cancer.


ECOG-ACRIN is renowned for advancing precision medicine and biomarker research through its leadership of major clinical trials that integrate cutting-edge genomic approaches. Through the CompassHER2 (COMprehensive use of Pathologic response ASSessment to escalate or de-escalate therapy in HER2-positive breast cancer) Trial Program, ECOG-ACRIN is collaborating with the Alliance for Clinical Trials in Oncology to investigate the optimization of therapy in patients with HER2+ breast cancer. The CompassHER2 pCR Trial (NCT04266249) was the first to open in this program, funded by the National Cancer Institute, part of the US National Institutes of Health.

Web:, X: @eaonc. Other: Facebook, LinkedIn, and Instagram.


REVEAL GENOMICS, S.L. is a biotechnology start-up seeking to change the way biomarkers are used in oncology. It is focused on developing innovative diagnostic tools to define the best therapeutic options for patients with cancer. The company uses pioneering techniques, sophisticated computer applications, and machine learning to reveal new cancer research data.

REVEAL GENOMICS, S.L. is a spin-off company of Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona (U.B.), and Vall d’Hebron Institute of Oncology (VHIO).

REVEAL GENOMICS® and HER2DX® are registered trademarks of REVEAL GENOMICS, S.L.

Web: @revealgenomics

To view this piece of content from, please give your consent at the top of this page.

Contact information

Further information: Adriana Herrera,

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AXON Aviation Group transfers business aircraft division to Jetcraft26.5.2024 14:00:00 CEST | Press release

AXON Aviation Group (AXON) has selected Jetcraft to take on its business jet activity as it seeks to streamline its service offering. The company will transfer all business aircraft sales and acquisitions to Jetcraft ensuring a smooth handover period for clients. This press release features multimedia. View the full release here: (L) Niki Rokni, Partner and Head of Aircraft Sales at AXON and (R) Jahid Fazal-Karim, Owner and Chairman of the Board at Jetcraft (Photo: Business Wire) Niki Rokni, Partner and Head of Aircraft Sales at AXON, says: “Jetcraft is the global leader in business jet transactions and is a natural fit to take on our respected clients. The AXON team will remain the same, now with additional focus on our commercial aircraft sales and leasing services.” The handover follows many years of successful collaboration between AXON and Jetcraft in navigating complex transactions around the world. AXON, who specialize in

Coco Rocha, Burak Özdemir, Lena Situations at the WIBA Awards 2024 Ceremony26.5.2024 01:08:00 CEST | Press release

The sixth annual WIBA Awards for social media personalities on a mission to change the world took place on May 24th, 2024, at the iconic Hotel Martinez during the Cannes Film Festival. The event gathered hundreds of top global content creators responsible for the year’s most viral moments. The evening featured a cocktail reception, a Gala Dinner, and the Awards ceremony with a special performance by Sonique. This press release features multimedia. View the full release here: WIBA 2024 Winners (Photo: Business Wire) The event awarded international celebrities and extraordinary personalities such as Coco Rocha, Lena Mahfouf (Situations), Alexandre Maras, Hyram, Sasha Ray and others. The Grand Prix WIBA title 2024 assigned to Burak Ozdemir, Turkish chef and restaurateur with over 129M followers on social media. WIBA Awards were overseen by the World Influencers Association (WIBA) based in Monaco. It was the first and the only inter

SLB OneSubsea Awarded Contract for Phase 3, Stage 2 of Equinor’s North Sea Troll Project24.5.2024 14:00:00 CEST | Press release

Regulatory News: This press release features multimedia. View the full release here: SLB OneSubsea is leveraging North Sea compliant, configurable equipment for Equinor’s North Sea Troll project. (Photo: Business Wire) SLB (NYSE: SLB) has announced the award of a sizeable contract by Equinor to its OneSubsea™ joint venture. The award leverages an existing long-term contract for the execution of the second stage of Phase 3 for Equinor’s Troll project in the North Sea, offshore Norway. To accelerate field delivery of the subsea tieback to existing infrastructure, SLB OneSubsea will leverage configurable solutions compliant with NCS2017+ for standardized subsea production systems for application in the Norwegian Continental Shelf (NCS). The objective for Troll Phase 3, Stage 2 is to accelerate production from the reservoir equivalent to about 55 billion standard cubic meters of gas. “We deeply appreciate our long-standing relations

Alipay Supports Xi’an to Build “International Consumer Friendly Tourist Destination”24.5.2024 13:15:00 CEST | Press release

Alipay, the leading digital payment and lifestyle service platform, today announced that it is working with Xi’an, the world-renowned ancient capital city located in Shaanxi province famous for the Terracotta Warriors, to launch the “International Consumer Friendly Tourist Destination” initiative. With the resurgence of inbound tourism to China, the initiative aims to enhance the travel and shopping experiences of international visitors to Xi’an and boost the city’s tourism industry. This press release features multimedia. View the full release here: Launch ceremony of “International Consumer Friendly Tourist Destination” Xi’an (Photo: Business Wire) Alipay – with the support and guidance of local authorities – is working with its partners in Xi’an, including tourist attractions, hotels, restaurants, and public transit agencies, to upgrade their payment and digital services for international travelers. International visitors can

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO ®24.5.2024 12:05:00 CEST | Press release

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts highlighting the breadth and depth of the company’s screening and diagnostic portfolio at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, Ill. Presentations will include new data confirming both the predictive and prognostic value of the Oncotype DX Breast Recurrence Score® test in racially and ethnically diverse patients. Exact Sciences will also present data on its approach to multi-cancer early detection (MCED) across multiple tumor types, plus additional real-world evidence showing optimized screening adherence strategies for the Cologuard® test as well as high adherence rates for repeat screenings. “Exact Sciences’ growing evidence shows that earlier and more personalized treatment interventions lead to greater success for people living with cancer. Therefore, effective cancer screening and di

HiddenA line styled icon from Orion Icon Library.Eye